Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

NCT01735630 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: ELND005
DRUG: Placebo

Sponsor

OPKO Health, Inc.

Collaborators

[object Object]